vs
Aligos Therapeutics, Inc.（ALGS）与Amesite Inc.（AMST）财务数据对比。点击上方公司名可切换其他公司
Aligos Therapeutics, Inc.的季度营收约是Amesite Inc.的1.6倍（$169.0K vs $108.0K），Amesite Inc.同比增速更快（746.8% vs -72.1%），过去两年Amesite Inc.的营收复合增速更高（-32.5% vs -50.7%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
Amesite Inc是一家总部位于美国的教育科技企业，主营人工智能驱动的云学习管理系统与定制化在线学习解决方案，服务覆盖高等院校、企业客户及政府机构，提供个性化技能提升、职业培训与学术课程交付服务。
ALGS vs AMST — 直观对比
营收规模更大
ALGS
是对方的1.6倍
$108.0K
营收增速更快
AMST
高出818.9%
-72.1%
两年增速更快
AMST
近两年复合增速
-50.7%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $108.0K |
| 净利润 | — | $-732.5K |
| 毛利率 | — | — |
| 营业利润率 | — | -689.7% |
| 净利率 | — | -678.0% |
| 营收同比 | -72.1% | 746.8% |
| 净利润同比 | 75.8% | 34.7% |
| 每股收益（稀释后） | — | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGSAMST
| Q4 25 | $169.0K | $108.0K | ||
| Q3 25 | $741.0K | $94.3K | ||
| Q2 25 | $965.0K | $55.8K | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $694.0K | — |
净利润ALGSAMST
| Q4 25 | — | $-732.5K | ||
| Q3 25 | $-31.5M | $-642.3K | ||
| Q2 25 | $-15.9M | $-924.0K | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $-34.9M | — |
营业利润率ALGSAMST
| Q4 25 | — | -689.7% | ||
| Q3 25 | -3827.4% | -702.2% | ||
| Q2 25 | -1924.0% | -1538.2% | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | — | ||
| Q1 24 | -3176.7% | — |
净利率ALGSAMST
| Q4 25 | — | -678.0% | ||
| Q3 25 | -4256.0% | -681.1% | ||
| Q2 25 | -1643.8% | -1657.1% | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | — | ||
| Q1 24 | -5023.5% | — |
每股收益（稀释后）ALGSAMST
| Q4 25 | — | $-0.16 | ||
| Q3 25 | $-3.04 | $-0.14 | ||
| Q2 25 | $-1.53 | $-0.13 | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $1.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.5M | $1.5M |
| 总资产 | $88.5M | $2.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALGSAMST
| Q4 25 | $77.8M | $1.2M | ||
| Q3 25 | $99.1M | $1.8M | ||
| Q2 25 | $122.9M | $2.3M | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | — | ||
| Q1 24 | $112.7M | — |
股东权益ALGSAMST
| Q4 25 | $53.5M | $1.5M | ||
| Q3 25 | $71.8M | $2.2M | ||
| Q2 25 | $101.9M | $2.7M | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | — | ||
| Q3 24 | $50.1M | — | ||
| Q2 24 | $67.2M | — | ||
| Q1 24 | $59.8M | — |
总资产ALGSAMST
| Q4 25 | $88.5M | $2.0M | ||
| Q3 25 | $109.8M | $2.6M | ||
| Q2 25 | $134.7M | $3.1M | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $108.8M | — | ||
| Q1 24 | $127.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-82.5M | $-621.1K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ALGSAMST
| Q4 25 | $-82.5M | $-621.1K | ||
| Q3 25 | $-24.3M | $-415.8K | ||
| Q2 25 | $-15.5M | $-439.4K | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-20.1M | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-22.7M | — |
现金转化率ALGSAMST
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
